Novo for sure knows who we are because we are using their Wegovy weight loss drug in a combo trial along with our monotrial. I am sure they will be watching closely for the outcome of SKYE's data. Also, SKYE's collaboration with Arecor is interesting because Eli Lilly and Sanofi are also in collaboration with Arecor for other meds, well Eli and Sanofi are both VERY interested in weight loss meds. So, let's see how this plays out. If SKYE can have a drug that supports weight loss without the psychiatric effects, I think we will be golden. These 2A results are going to be HUGE. I think there are a lot of big companies watching. And I think one will pull the trigger on SKYE a lot sooner than later. Probably before the 2A results come out. We will see. $NVO $SKYE